Related Experiment Video
Updated: Jun 21, 2025
Author Spotlight: THP-1 Macrophage Response to LPS/ATP — Unveiling the Pyroptosis, Apoptosis, and Necroptosis Spectrum
Published on: May 3, 2024
Harnessing pyroptosis for lung cancer therapy: The impact of NLRP3 inflammasome activation
Rajiv Dahiya1, Vijaykumar B Sutariya2, Sheeba Varghese Gupta2
1School of Pharmacy, Faculty of Medical Sciences, The University of the West Indies, St. Augustine, Trinidad & Tobago, West Indies.
Abstract:
Lung cancer is still a global health challenge in terms of high incidence, morbidity, and mortality. Recent scientific studies have determined that pyroptosis, a highly inflammatory form of programmed cell death, can be identified as a potential lung cancer therapeutic target. The NLRP3 inflammasome acts as a critical mediator in this process and, upon activation, activates multiprotein complex formation as well as caspase-1 activation. This process, triggered by a release of pro-inflammatory cytokines, results in pyroptotic cell death. Also, the relationship between the NLRP3 inflammasome and lung cancer was justified by its influence on tumour growth or metastasis. The molecular pathways produce progenitive mediators and remake the tissue. Finally, targeting NLRP3 inflammasome for pyroptosis induction and inhibition of its activation appears to be a promising lung cancer treatment approach. This technique makes cancer treatment more promising and personalized. This review explores the role of NLRP3 inflammasome activation and its possibilities in lung cancer treatment.
Insights
Targeting pyroptosis via the NLRP3 inflammasome offers a promising new approach for lung cancer treatment. This strategy aims to induce cell death and inhibit tumor growth, personalizing cancer therapy.
Area of Science:
- Oncology
- Immunology
- Cell Biology
Background:
- Lung cancer remains a significant global health burden with high mortality rates.
- Pyroptosis, a pro-inflammatory programmed cell death, is increasingly recognized for its role in cancer.
- The NLRP3 inflammasome is a key mediator in pyroptosis, influencing cancer progression.
Purpose of the Study:
- To explore the role of NLRP3 inflammasome activation in lung cancer.
- To review the therapeutic potential of targeting pyroptosis for lung cancer treatment.
Main Methods:
- This review synthesizes current scientific literature on NLRP3 inflammasome, pyroptosis, and lung cancer.
- It examines molecular pathways and experimental evidence linking NLRP3 inflammasome to tumor growth and metastasis.
Main Results:
- NLRP3 inflammasome activation leads to caspase-1 activation and pyroptotic cell death.
- The NLRP3 inflammasome influences lung cancer progression, including tumor growth and metastasis.
- Inducing pyroptosis via NLRP3 inflammasome targeting shows therapeutic promise.
Conclusions:
- Targeting the NLRP3 inflammasome for pyroptosis induction is a potential personalized lung cancer treatment strategy.
- Inhibiting NLRP3 inflammasome activation may offer a novel therapeutic avenue for lung cancer.
- Further research into this pathway could lead to more effective lung cancer therapies.
